Orphazyme A/S (Nasdaq Copenhagen: ORPHA.CO) (Copenhagen, Denmark) is a biopharmaceutical company with a late-stage drug pipeline, developing new treatment options for orphan protein-misfolding diseases. 

The company develops new therapies that mobilize a group of stress-response proteins, called heat-shock proteins. Heat-shock proteins help restore balance to cells affected by stress arising from misfolded proteins, protein aggregates, and lysosomal dysfunction.

The lead compound, Arimoclomol, is in clinical development in Niemann-Pick Type C, ALS, sIBM and Gaucher.


For more information, please contact:

Sten Verland, PhD MSc

General Partner

Phone +45 2422 1969